The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

Being the second most common type of primary bone malignancy in children and adolescents, Ewing Sarcoma (ES) encounters the dilemma of low survival rate with a lack of effective treatments. As an emerging approach to combat cancer, RNA therapeutics may expand the range of druggable targets. Since th...

Full description

Bibliographic Details
Main Authors: Dai-Feng Li, Ying Yuan, Mei-Juan Tu, Xiang Hu, Yi-Zhou Li, Wan-Rong Yi, Peng-Cheng Li, Yong Zhao, Zhen Cheng, Ai-Ming Yu, Chao Jian, Ai-Xi Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
RNA therapy
miR-34a
bioengineered
apoptosis
Ewing Sarcoma
mouse model
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00222/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00222/full

Similar Items